{"id":2716,"date":"2011-01-07T11:21:50","date_gmt":"2011-01-07T16:21:50","guid":{"rendered":"http:\/\/sciencebusiness.technewslit.com\/?p=2716"},"modified":"2011-01-08T21:53:43","modified_gmt":"2011-01-09T02:53:43","slug":"spirogen-genentech-partner-on-anti-cancer-therapies","status":"publish","type":"post","link":"https:\/\/technewslit.com\/sciencebusiness\/?p=2716","title":{"rendered":"Spirogen, Genentech Partner on Anti-Cancer Therapies"},"content":{"rendered":"<p><a href=\"http:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2010\/07\/LabGlass_200x250.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"alignright size-full wp-image-345\" title=\"LabGlass_200x250\" src=\"http:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2010\/07\/LabGlass_200x250.jpg\" alt=\"Beakers and test tubes (Horia Varlan\/Flickr)\" width=\"200\" height=\"250\" srcset=\"https:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2010\/07\/LabGlass_200x250.jpg 200w, https:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2010\/07\/LabGlass_200x250-120x150.jpg 120w\" sizes=\"auto, (max-width: 200px) 100vw, 200px\" \/><\/a>Spirogen Ltd. a London, U.K. biotechnology company, announced a multi-year <a href=\"http:\/\/www.spirogen.com\/press.php\">research collaboration and license agreement<\/a> with Genentech, a Roche Group company, to discover and develop <a href=\"http:\/\/pubs.acs.org\/doi\/abs\/10.1021\/bc9002019\">antibody drug conjugates<\/a> (ADCs) as potential anti-cancer agents.<\/p>\n<p>The collaboration will make use of Spirogen&#8217;s pyrrolobenzodiazepine (PBD) drugs,\u00a0 a group of natural antibiotics, and associated linking technology. Under the agreement, Spirogen will synthesize and manufacture drug reagents, while Genentech will use Spirogen&#8217;s drug reagents to generate ADCs and evaluate their therapeutic potential. Genentech will have an exclusive license to fully develop and commercialize licensed products that contain these ADCs.<\/p>\n<p>Terms of the multi-year collaboration include an initial one-time license fee, development milestones on reaching pre-defined targets, and further milestones and royalties for licensed products. The amounts of those payments were not disclosed.<\/p>\n<p>Photo: <a href=\"http:\/\/www.flickr.com\/photos\/horiavarlan\/4273968004\/\">Horia Varlan\/Flickr<\/a><\/p>\n<p style=\"text-align: center;\">*\u00a0\u00a0\u00a0\u00a0 *\u00a0\u00a0\u00a0\u00a0 *<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Spirogen Ltd. a London, U.K. biotechnology company, announced a multi-year research collaboration and license agreement with Genentech, a Roche Group company, to discover and develop antibody drug conjugates (ADCs) as potential anti-cancer agents. The collaboration will make use of Spirogen&#8217;s pyrrolobenzodiazepine (PBD) drugs,\u00a0 a group of natural antibiotics, and associated linking technology. Under the agreement, [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,16],"tags":[31,21,51,45,84,27,90],"class_list":["post-2716","post","type-post","status-publish","format-standard","hentry","category-i-p","category-ventures","tag-biomedical","tag-biotech","tag-cancer","tag-europe","tag-licensing","tag-pharmaceuticals","tag-u-k"],"_links":{"self":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/2716","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2716"}],"version-history":[{"count":5,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/2716\/revisions"}],"predecessor-version":[{"id":2720,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/2716\/revisions\/2720"}],"wp:attachment":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2716"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2716"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2716"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}